1. Home
  2. VSECU vs ARDX Comparison

VSECU vs ARDX Comparison

Compare VSECU & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VSE Corporation Tangible Equity Units

VSECU

VSE Corporation Tangible Equity Units

N/A

Current Price

$53.75

Market Cap

1.6B

Sector

N/A

ML Signal

N/A

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$5.29

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSECU
ARDX
Founded
N/A
2007
Country
United States
United States
Employees
1600
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
VSECU
ARDX
Price
$53.75
$5.29
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$15.14
AVG Volume (30 Days)
38.2K
4.8M
Earning Date
N/A
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,607,000.00
Revenue This Year
N/A
$37.75
Revenue Next Year
N/A
$34.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.45
$4.08
52 Week High
$68.10
$8.40

Technical Indicators

Market Signals
Indicator
VSECU
ARDX
Relative Strength Index (RSI) 51.90 39.44
Support Level $44.69 $4.89
Resistance Level $58.94 $5.34
Average True Range (ATR) 3.58 0.31
MACD -0.42 -0.02
Stochastic Oscillator 8.45 23.45

Price Performance

Historical Comparison
VSECU
ARDX

About VSECU VSE Corporation Tangible Equity Units

VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: